This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. Lombardi is the only NCI-designated cancer center in the nation's capital and in the Washington metropolitan area. The District of Columbia has among the highest cancer mortality rates in the country. Thus, there is a clear need for an NCI-designated comprehensive cancer center that can bring a targeted, evidence-based strategy to cancer care and prevention to help improve the health of the community's residents. In the present application, Lombardi comprises 177 members (113 full members), participating in six research programs with the support of 12 shared resources, based primarily in two adjacent buildings. Peer-reviewed research annual direct funding for 2008 totaled $53 million, with $28.5 million coming from the NCI. This represents a significant increase in NCI funding compared with 2002. Lombardi clinical activities are carried out in conjunction with GU's clinical partner, MedStar Health, Inc. In FY02, Lombardi clinical services served more than 22,000 outpatient cancer visits, and 603 patients were enrolled on Lombardi clinical trials. Outpatient cancer visits have increased to 39,000 in 2008, with 1,169 people placed on interventional trials. Georgetown University's (GU) unwavering high level of commitment to the success of Lombardi is exemplified by the recruitment of a new Director, Louis Weiner, M.D., in January 2008. He also chairs the GU Department of Oncology, with the authority to recruit faculty, control space, and oversee resource allocation to support Lombardi's mission. Several recent high-profile recruitments attest to Lombardi's ability to attract outstanding researchers. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science, coupled with new cross-cutting initiatives in health disparities and systems medicine. Lombardi's researchers published almost 2,000 peer-reviewed manuscripts (24% intraprogrammatic and 22% interprogrammatic) in the current funding period, exerting a sustained and powerful influence on the cancer research fields highlighted in this application, such as the development of human papillomavirus vaccines. With continued CCSG support, Lombardi will continue to make outstanding, high-impact contributions to cancer research.

Public Health Relevance

This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG, led by Louis Weiner, M.D. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science. Each program brings together cancer researchers who focus on distinct areas, coupled with new cross-cutting initiatives in health disparities and systems medicine. With continued CCSG support, Lombardi will continue to make outstanding, high impact contributions to cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8256586
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-08-15
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$1,550,491
Indirect Cost
$539,910
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904
AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86
Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the "Internet of Things" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866
Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70
Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71
Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50
Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:
Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190

Showing the most recent 10 out of 883 publications